Misplaced Pages

Aminoxytriphene: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 18:39, 19 December 2024 editIdoghor Melody (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers33,655 editsm clean upTag: AWB← Previous edit Revision as of 20:22, 19 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,799 edits templated citesNext edit →
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = Aminoxytriphene | drug_name = Aminoxytriphene
Line 58: Line 59:
| StdInChIKey = FRQGJOFRWIILCX-UHFFFAOYSA-N | StdInChIKey = FRQGJOFRWIILCX-UHFFFAOYSA-N
}} }}
Amotriphene is a coronary vasodilator that was developed at Sterling Drug in the early 1960s.<ref>Elpern Bill, US3010965 & US3161646 (1961 & 1964 both to Sterling Drug Inc).</ref> It has selective binding to alpha-adrenergic receptors.<ref>Greenslade, Forrest C.; Newquist, Kathryn L.; Krider, Kathryn M.; Chasin, Mark; Scott, Cynthia K. (1982). "Heterogeneity of Biochemical Actions Among Vasodilators". Journal of Pharmaceutical Sciences. 71 (1): 94–100. doi:10.1002/jps.2600710123.</ref> Amotriphene is a coronary vasodilator that was developed at Sterling Drug in the early 1960s.<ref>Elpern Bill, US3010965 & US3161646 (1961 & 1964 both to Sterling Drug Inc).</ref> It has selective binding to alpha-adrenergic receptors.<ref name="pmid6276530">{{cite journal | vauthors = Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M | title = Heterogeneity of biochemical actions among vasodilators | journal = Journal of Pharmaceutical Sciences | volume = 71 | issue = 1 | pages = 94–100 | date = January 1982 | pmid = 6276530 | doi = 10.1002/jps.2600710123 | url = }}</ref>


It has a structure that is similar to ] (that is to say it is a ]), although it is not thought to function as a non-steroidal synthetic estrogen. It has a structure that is similar to ] (that is to say it is a ]), although it is not thought to function as a non-steroidal synthetic estrogen.


Pharmacology:<ref>Sandler, Gerald (1960). "Clinical evaluation of a new coronary vasodilator, 3-dimethylamino-1,1 2-tris (4-methoxyphenyl)-1-propene hydrochloride (WIN 5494)". American Heart Journal. 59 (5): 718–722. doi:10.1016/0002-8703(60)90512-3.</ref><ref>Karczmar, A. G.; Bourgault, P.; Elpern, B. (1958). "Antiaccelerator, Coronary Dilator and Certain Other Pharmacologic Actions of New Poly-Methoxyphenyl Derivatives". Experimental Biology and Medicine. 98 (1): 114–118. doi:10.3181/00379727-98-23957.</ref><ref>DAY HW. Angina pectoris. A clinical note in the use of Myordil (Win 5494). J Kans Med Soc. 1961 Apr;62:143. PMID 13720339.</ref><ref>Ruskin, Arthur (1961). "Effects of Erythrol Tetranitrate and Amotriphene on Exercise Tolerance Tests in Angina Pectoris". Circulation. 23 (5): 681–684. doi:10.1161/01.CIR.23.5.681.</ref><ref>HARRIS R. Clinical observations of amotriphene hydrochloride. N Y State J Med. 1961 Dec 1;61:4009-14. PMID 13904871.</ref> Pharmacology:<ref name="pmid14441425">{{cite journal | vauthors = Sandler G | title = Clinical evaluation of a new coronary vasodilator, 3-dimethylamino-1,1 2-tris (4-methoxyphenyl)-1-propene hydrochloride (WIN 5494) | journal = American Heart Journal | volume = 59 | issue = | pages = 718–22 | date = May 1960 | pmid = 14441425 | doi = 10.1016/0002-8703(60)90512-3 }}</ref><ref name="pmid13554559">{{cite journal | vauthors = Karczmar AG, Bourgault P, Elpern B | title = Antiaccelerator, coronary dilator and certain other pharmacologic actions of new poly-methoxyphenyl derivatives | journal = Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) | volume = 98 | issue = 1 | pages = 114–8 | date = May 1958 | pmid = 13554559 | doi = 10.3181/00379727-98-23957 | url = }}</ref><ref name="pmid13720339">{{cite journal | vauthors = Day HW | title = Angina pectoris. A clinical note in the use of Myordil (Win 5494) | journal = The Journal of the Kansas Medical Society | volume = 62 | issue = | pages = 143 | date = April 1961 | pmid = 13720339 | doi = | url = }}</ref><ref name="pmid13744809">{{cite journal | vauthors = Ruskin A | title = Effects of erythrol tetranitrate and amotriphene on exercise tolerance tests in angina pectoris | journal = Circulation | volume = 23 | issue = | pages = 681–4 | date = May 1961 | pmid = 13744809 | doi = 10.1161/01.cir.23.5.681 | url = }}</ref><ref name="pmid13904871">{{cite journal | vauthors = Harris R | title = Clinical observations of amotriphene hydrochloride | journal = New York State Journal of Medicine | volume = 61 | issue = | pages = 4009–14 | date = December 1961 | pmid = 13904871 | doi = | url = }}</ref>


== References == == References ==

Revision as of 20:22, 19 December 2024

Pharmaceutical compound
Aminoxytriphene
Clinical data
Other namesAmotriphene, Myordil, Win 5494, Rimalcor.
Identifiers
IUPAC name
  • 2,3,3-tris(4-methoxyphenyl)-N,N-dimethylprop-2-en-1-amine
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H29NO3
Molar mass403.522 g·mol
3D model (JSmol)
SMILES
  • CN(C)CC(=C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC
InChI
  • InChI=1S/C26H29NO3/c1-27(2)18-25(19-6-12-22(28-3)13-7-19)26(20-8-14-23(29-4)15-9-20)21-10-16-24(30-5)17-11-21/h6-17H,18H2,1-5H3
  • Key:FRQGJOFRWIILCX-UHFFFAOYSA-N

Amotriphene is a coronary vasodilator that was developed at Sterling Drug in the early 1960s. It has selective binding to alpha-adrenergic receptors.

It has a structure that is similar to Chlorotrianisene (that is to say it is a triphenylethylene), although it is not thought to function as a non-steroidal synthetic estrogen.

Pharmacology:

References

  1. Elpern Bill, US3010965 & US3161646 (1961 & 1964 both to Sterling Drug Inc).
  2. Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M (January 1982). "Heterogeneity of biochemical actions among vasodilators". Journal of Pharmaceutical Sciences. 71 (1): 94–100. doi:10.1002/jps.2600710123. PMID 6276530.
  3. Sandler G (May 1960). "Clinical evaluation of a new coronary vasodilator, 3-dimethylamino-1,1 2-tris (4-methoxyphenyl)-1-propene hydrochloride (WIN 5494)". American Heart Journal. 59: 718–22. doi:10.1016/0002-8703(60)90512-3. PMID 14441425.
  4. Karczmar AG, Bourgault P, Elpern B (May 1958). "Antiaccelerator, coronary dilator and certain other pharmacologic actions of new poly-methoxyphenyl derivatives". Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 98 (1): 114–8. doi:10.3181/00379727-98-23957. PMID 13554559.
  5. Day HW (April 1961). "Angina pectoris. A clinical note in the use of Myordil (Win 5494)". The Journal of the Kansas Medical Society. 62: 143. PMID 13720339.
  6. Ruskin A (May 1961). "Effects of erythrol tetranitrate and amotriphene on exercise tolerance tests in angina pectoris". Circulation. 23: 681–4. doi:10.1161/01.cir.23.5.681. PMID 13744809.
  7. Harris R (December 1961). "Clinical observations of amotriphene hydrochloride". New York State Journal of Medicine. 61: 4009–14. PMID 13904871.
Vasodilators used in cardiac diseases (C01D)
Nitrovasodilators
Quinolone vasodilators
Others
Categories: